UNICA IRIS Institutional Research Information System

CHESSA, LUCHINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 218.874
NA - Nord America 12.627
AS - Asia 6.935
SA - Sud America 1.336
AF - Africa 236
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 7
Totale 240.052
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 213.656
US - Stati Uniti d'America 12.368
SG - Singapore 2.749
CN - Cina 2.148
NL - Olanda 1.167
BR - Brasile 1.007
SE - Svezia 859
UA - Ucraina 745
VN - Vietnam 681
DE - Germania 589
FI - Finlandia 518
GB - Regno Unito 498
FR - Francia 385
HK - Hong Kong 323
IN - India 182
CA - Canada 144
KR - Corea 139
AR - Argentina 115
BD - Bangladesh 101
AT - Austria 79
IQ - Iraq 75
MX - Messico 73
ZA - Sudafrica 71
RU - Federazione Russa 63
ID - Indonesia 59
JP - Giappone 59
TR - Turchia 58
CO - Colombia 47
MA - Marocco 47
EC - Ecuador 46
PL - Polonia 46
IE - Irlanda 44
PK - Pakistan 44
ES - Italia 41
VE - Venezuela 35
AU - Australia 34
CL - Cile 33
PH - Filippine 33
SA - Arabia Saudita 32
UZ - Uzbekistan 28
MY - Malesia 27
KE - Kenya 24
CZ - Repubblica Ceca 23
BE - Belgio 22
PY - Paraguay 21
EG - Egitto 20
IR - Iran 20
TN - Tunisia 19
AZ - Azerbaigian 17
IL - Israele 17
LT - Lituania 16
TW - Taiwan 16
JO - Giordania 15
KZ - Kazakistan 14
PE - Perù 12
RO - Romania 12
TH - Thailandia 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
DK - Danimarca 11
DZ - Algeria 10
LB - Libano 10
KG - Kirghizistan 9
OM - Oman 9
PA - Panama 9
AO - Angola 8
PT - Portogallo 8
RS - Serbia 8
TT - Trinidad e Tobago 8
AL - Albania 7
BG - Bulgaria 7
BO - Bolivia 7
JM - Giamaica 7
MD - Moldavia 7
SY - Repubblica araba siriana 7
GR - Grecia 6
HR - Croazia 6
KW - Kuwait 6
BY - Bielorussia 5
HU - Ungheria 5
LV - Lettonia 5
MK - Macedonia 5
NP - Nepal 5
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
CG - Congo 4
CR - Costa Rica 4
ET - Etiopia 4
MU - Mauritius 4
NO - Norvegia 4
PS - Palestinian Territory 4
SI - Slovenia 4
UG - Uganda 4
AP - ???statistics.table.value.countryCode.AP??? 3
DO - Repubblica Dominicana 3
EU - Europa 3
GE - Georgia 3
HN - Honduras 3
LC - Santa Lucia 3
Totale 239.995
Salva come PNG Salva come JPEG
Città #
Cagliari 206.917
Uta 5.009
Singapore 1.286
Dallas 1.153
Ashburn 1.144
Amsterdam 1.094
Fairfield 915
Woodbridge 783
Chandler 734
San Jose 724
Boardman 653
Houston 604
Nyköping 520
Ann Arbor 408
Jacksonville 394
Beijing 381
Seattle 357
Helsinki 354
Wilmington 353
Cambridge 294
Hong Kong 287
Los Angeles 281
Ho Chi Minh City 211
Lauterbourg 203
Boston 201
Santa Clara 199
Hefei 196
Dearborn 192
New York 191
Council Bluffs 178
Munich 178
Shanghai 160
Rome 159
Nanjing 150
The Dalles 149
Hanoi 125
Seoul 123
Milan 118
Buffalo 117
São Paulo 102
San Diego 83
Dong Ket 78
Frankfurt am Main 76
Redwood City 73
Guangzhou 64
Orem 63
London 60
Mansfield 57
Nanchang 52
Nuremberg 52
Toronto 50
Tianjin 48
Turku 48
Vienna 47
Redondo Beach 46
Tokyo 45
Chicago 42
Jiaxing 40
Changsha 39
Oxford 38
Shenyang 38
Hebei 37
Montreal 37
Warsaw 37
Paris 36
Norwalk 35
Atlanta 33
Rio de Janeiro 33
Chennai 32
Dublin 32
Johannesburg 32
Da Nang 30
Baghdad 29
Casablanca 29
Manchester 27
Washington 27
Brooklyn 26
Sassari 26
Haiphong 24
Tashkent 24
Dhaka 23
Orange 23
Belo Horizonte 22
Denver 22
Mountain View 22
Nottingham 22
San Mateo 22
Birmingham 21
Nairobi 21
Verona 21
Düsseldorf 20
Mexico City 20
Santiago 20
Stockholm 20
Basingstoke 19
Jakarta 19
Naples 19
Quito 19
Brussels 18
Lappeenranta 18
Totale 229.733
Salva come PNG Salva come JPEG
Nome #
Comparing the responses of countries and National Health Systems to the COVID-19 pandemic: a critical analysis with a case-report series 20.818
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.562
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.363
Gastrointestinal Coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management 3.290
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ? 3.141
HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis 3.135
Altered profile of salivary proteins in patients with Autoimmune Hepatitis 2.950
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible? 2.931
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis 2.826
Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study 2.742
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients 2.723
Hippocampal axis dysfunction evaluation by Rey-Osterrieth Complex figure test (RCFT) should be included in minimal hepatic encephalopathy (MHE) assessment 2.639
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA 2.595
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis 2.546
Behavior of bone mass in long-term HAART patients 2.498
Association of chronic hepatitis C with recurrent brief depression 2.469
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI 2.431
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma 2.415
Role of HLA-G in autmoimmune hepatitis 2.307
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ? 2.299
Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis 2.205
Dynamics of TT virus infection in a cohort of HCV-infected patients achieving sustained virologic responce after treatment with direct-acting antivirals 2.166
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C 2.158
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 2.017
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection treated with direct antiviral agents 2.009
A multivariate approach for the brain impairment in patients with liver cirrhosi 1.985
La neopterina uraria come marker di attività immunologica nelle malattie infiammatorie croniche dell’intestino 1.949
Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis 1.918
Is the Inversion in the Trend of the Lethality of the COVID-19 in the Two Hemispheres due to the Difference in Seasons and Weather? 1.905
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.826
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in co-infected HIV-HCV patients treated with the new direct acting antivirals (DAAs) 1.766
Long-latency potential study in minimal hepatic hencephalopaty 1.744
null 1.742
null 1.710
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? 1.702
The climate in the European Union and the enlarged European Region is a determinant of the COVID-19 case fatality ratio 1.699
The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study 1.685
null 1.666
SAFETY AND EFFICACY OF PEG-IFN alpha 2a AND RIBAVIRIN FOR TREATMENT OF HEPATITIS C IN SARDINIAN ADULT PATIENTS WITH THALASSEMIA MAJOR: A SINGLE CENTRE REAL LIFE EXPERIENCE 1.651
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.640
Multidimensional geriatric assessment in elderly HIV patients 1.622
null 1.610
Evolution of the viral quasispecies tracked by sequence analysis during interferon treatment of chronic hepatitis C. 1.607
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 1.544
The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature 1.534
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 1.526
HepaDisk – A new quality of life questionnaire for HCV patients 1.521
EVALUATION OF MILD COGNITIVE DYSFUNCTION BY MONTREAL COGNITIVE ASSESSMENT TEST IN PATIENTS WITH CHRONIC HCV INFECTION 1.511
Orthotopic liver transplantation in neurological Wilson desease: case report 1.491
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection 1.442
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 1.432
null 1.424
Individualized long-term treatment of chronic hepatitis C with interferon alpha (IFN alpha)-2a. 1.411
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 1.378
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 1.366
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination 1.345
Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database 1.327
Evolution of the HCV quasispecies and pattern of response to interferon therapy in patients with chronic hepatitis C 1.322
Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination 1.314
Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort. 1.305
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 1.299
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy 1.284
Can antiretroviral therapy modify the clinical course of HDV infection in HIV positive patients? 1.278
La quasispecie del virus dell’epatite C: implicazioni biologiche e cliniche 1.243
A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population 1.226
null 1.208
Forecasting liver disease burden 1.197
Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: Data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort 1.184
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 1.134
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy 1.130
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 1.109
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 1.108
Epidemiological and Economic Evaluations According to Daa Treatment Access in Italy Based on Real Life Piter Cohort Data 1.095
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 1.089
A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G 1.088
Risultati preliminari di uno studio di fase II con Sorafenib in pazienti anziani affetti da epatocarcinoma 1.075
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 1.074
Previous functional social and behavioral rhythms affect resilience to COVID-19-related stress among old adults 1.061
Long term effectiveness of DAA therapy in patients with chronic HCV and Mixed Cryoglobulinemic Syndrome 1.058
Clinical characterization and economic impact evaluation of antiHCV DAA treatment failure:real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) 1.047
Optimization of Hepatitis C Virus screening strategies by birth cohort in Italy 1.045
L'approccio basato sui casi per la diagnosi di malattie epatiche 1.021
Forecasting Hepatitis C liver disease burden based on real life data. Does the hidden iceberg matter to reach the World Health Organization elimination goals? 1.006
Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment 992
Mixed cryoglobulinemia: an important but frequently unrecognized and underestimated HCV-related condition in the real life practice 991
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 987
Combined Salivary Proteome Profiling and Machine Learning Analysis Provides Insight into Molecular Signature for Autoimmune Liver Diseases Classification 969
Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resources’ Allocation 956
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 947
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 935
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study 935
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV Gruppo 933
Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study 914
Iron concentration and distribution in the newborn liver 903
Modeling cost-effectiveness and health gains of a “universal“ versus “prioritized“ hepatitis C virus treatment policy in a real-life cohort 897
COVID-19 Vaccine Hesitancy among Italian Healthcare Workers: Latent Profiles and Their Relationships to Predictors and Outcome 893
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 885
The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis 885
Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 879
Gender differences in HCV chronic liver disease: a reallife evaluation in PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) Cohort study. 877
Totale 182.692
Salva come PNG Salva come JPEG
Categoria #
all - tutte 324.360
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 324.360
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217.461 0 0 0 0 0 0 0 0 0 2.960 2.694 1.807
2021/202213.215 1.217 1.135 703 1.000 958 985 865 724 1.097 996 1.535 2.000
2022/202319.438 2.076 2.643 2.596 1.408 1.692 1.926 893 1.655 1.133 1.086 1.435 895
2023/202422.027 1.023 1.137 1.230 1.719 2.007 3.667 3.457 1.523 1.022 1.463 1.747 2.032
2024/202558.197 7.306 29.122 5.040 4.491 2.321 2.498 3.731 305 643 1.622 494 624
2025/202613.131 1.015 933 1.898 1.238 1.113 1.207 2.685 723 1.127 1.192 0 0
Totale 240.728